{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T01:58:47Z","timestamp":1783216727606,"version":"3.54.6"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.urolonc.2023.05.019","type":"journal-article","created":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T01:40:11Z","timestamp":1686188411000},"page":"431.e7-431.e14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006\u20132018: Effect of race, age and socioeconomic status on treatment disparities"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9248-9338","authenticated-orcid":false,"given":"Onika DV","family":"Noel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary","family":"Cress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc A","family":"Dall'Era","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.urolonc.2023.05.019_bib0001","first-page":"7","article-title":"Cancer Statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"10061","key":"10.1016\/j.urolonc.2023.05.019_bib0002","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1016\/S0140-6736(16)30512-8","article-title":"Bladder cancer","volume":"388","author":"Kamat","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.urolonc.2023.05.019_bib0003","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1111\/bju.13760","article-title":"Guideline of guidelines: Non-muscle invasive bladder cancer","volume":"119","author":"Woldu","year":"2017","journal-title":"BJU"},{"issue":"4","key":"10.1016\/j.urolonc.2023.05.019_bib0004","first-page":"145","article-title":"Intravesical therapy for non-muscle invasive bladder cancer: Current and future options in the age of Bacillus-Calmette-Guerin shortage","volume":"21","author":"Golla","year":"2019","journal-title":"Rev Urol"},{"issue":"5","key":"10.1016\/j.urolonc.2023.05.019_bib0005","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.eururo.2018.06.024","article-title":"Treatment strategy for newly diagnosed T1 high-grade bladder urothelial carcinoma: New insights and updated recommendations","volume":"74","author":"Klaassen","year":"2018","journal-title":"Europ Assoc Urol"},{"issue":"9","key":"10.1016\/j.urolonc.2023.05.019_bib0006","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11934-016-0625-z","article-title":"High-risk non-muscle invasive bladder cancer: Therapy options during Intravesical BCG shortage","volume":"17","author":"Veeratterapillay","year":"2016","journal-title":"Curr Urol Rep"},{"issue":"2","key":"10.1016\/j.urolonc.2023.05.019_bib0007","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JOP.2011.000480","article-title":"Adjuvant intravesical Bacillus Calmette-Gu\u00e9rin therapy and survival among elderly patients with non-muscle invasive bladder cancer","volume":"9","author":"Spencer","year":"2013","journal-title":"J Oncol Prac"},{"issue":"6","key":"10.1016\/j.urolonc.2023.05.019_bib0008","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/bju.12012","article-title":"Current clinical practice gaps in the treatment of intermediate and high-risk non-muscle invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Gu\u00e9rin (BCG): Results of an international individual patient data survey (IPDS)","volume":"112","author":"Witjes","year":"2013","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.urolonc.2023.05.019_bib0009","doi-asserted-by":"crossref","first-page":"308e19","DOI":"10.1016\/j.urolonc.2018.03.008","article-title":"Sociodemographic disparities in chemotherapy treatment and impact on survival among patients with metastatic bladder cancer","volume":"36","author":"Klapheke","year":"2018","journal-title":"Urol Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2023.05.019_bib0010","doi-asserted-by":"crossref","first-page":"8310","DOI":"10.1002\/cam4.3429","article-title":"Race modifies survival benefit of guideline-based treatment: implications for reducing disparities in muscle invasive bladder cancer","volume":"9","author":"Washington","year":"2020","journal-title":"Cancer Med"},{"issue":"7","key":"10.1016\/j.urolonc.2023.05.019_bib0011","doi-asserted-by":"crossref","first-page":"343.e15","DOI":"10.1016\/j.urolonc.2022.02.008","article-title":"Disparities in patient and system factors explain racial\/ethnic disparities in delayed time to treatment in muscle invasive bladder cancer","volume":"40","author":"Buac","year":"2022","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2023.05.019_bib0012","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1002\/cncr.22449","article-title":"Factors affecting outcomes after radical cystectomy in African Americans","volume":"109","author":"Konety","year":"2007","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2023.05.019_bib0013","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.juro.2006.04.074","article-title":"Racial disparity in bladder cancer: Trends in tumor presentation at diagnosis","volume":"176","author":"Lee","year":"2006","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2023.05.019_bib0014","doi-asserted-by":"crossref","first-page":"469.e1","DOI":"10.1016\/j.urolonc.2018.07.012","article-title":"Racial disparity in quality of care and overall survival among black vs. white patients with muscle-invasive bladder cancer treated with radical cystectomy: A national cancer database analysis","volume":"36","author":"Gild","year":"2018","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2023.05.019_bib0015","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/cncr.24701","article-title":"Racial differences in treatment and outcomes among patient with early stage bladder cancer","volume":"116","author":"Hollenbeck","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.urolonc.2023.05.019_bib0016","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.urology.2019.03.035","article-title":"Care quality and variability in the use of intravesical therapy for initial treatment of nonmuscle invasive bladder cancer within a large, diverse integrated delivery system","volume":"131","author":"Danforth","year":"2019","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2023.05.019_bib0017","series-title":"Developing an area-based socioeconomic measure from American Community Survey data","author":"Yang","year":"2014"},{"issue":"9","key":"10.1016\/j.urolonc.2023.05.019_bib0018","doi-asserted-by":"crossref","first-page":"601","DOI":"10.2147\/CLEP.S146395","article-title":"Comorbidity index in central cancer registries: the value of hospital discharge data","volume":"20","author":"Lichtensztajn","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.urolonc.2023.05.019_bib0019","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.juro.2008.04.016","article-title":"Predictors of intravesical therapy for nonmuscle invasive bladder cancer: Results from the Surveillance, Epidemiology and End Results Program 2003 Patterns of Care Project","volume":"180","author":"Huang","year":"2008","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2023.05.019_bib0020","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/cncr.26402","article-title":"Quality of care in patients with bladder cancer","volume":"118","author":"Chamie","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2023.05.019_bib0021","doi-asserted-by":"crossref","first-page":"3177","DOI":"10.1007\/s00345-020-03130-1","article-title":"Analysis of age influence on oncological results and toxicity of BCG immunotherapy in non-muscle invasive bladder cancer","volume":"38","author":"Krajewski","year":"2020","journal-title":"World J Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2023.05.019_bib0022","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.urolonc.2007.04.005","article-title":"Effect of advanced age on the development of complications from intravesical bacillus Calmette- Gu\u00e9rin therapy","volume":"26","author":"Heiner","year":"2008","journal-title":"Urol Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2023.05.019_bib0023","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1007\/s11255-021-02870-2","article-title":"Oncological outcomes of high-grade T1 non-muscle invasive bladder cancer treatment in octogenarians","volume":"53","author":"Slusarczyk","year":"2021","journal-title":"Int Urol Nephrol"},{"issue":"31","key":"10.1016\/j.urolonc.2023.05.019_bib0024","doi-asserted-by":"crossref","first-page":"e16223","DOI":"10.1097\/MD.0000000000016223","article-title":"The impact of age on intravesical instillation of Bacille Calmette\u2013Gu\u00e9rin treatment in patients with high-grade T1 bladder cancer","volume":"98","author":"Cal\u00f2","year":"2019","journal-title":"Medicine (Baltimore)"},{"issue":"3","key":"10.1016\/j.urolonc.2023.05.019_bib0025","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bju.13474","volume":"118","author":"Oddens","year":"2016","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.urolonc.2023.05.019_bib0026","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.urology.2007.03.024","article-title":"Age and outcome of superficial bladder cancer treated with bacille Calmette-Gu\u00e9rin therapy","volume":"70","author":"Herr","year":"2007","journal-title":"Urology"},{"issue":"5","key":"10.1016\/j.urolonc.2023.05.019_bib0027","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jgo.2018.03.020","article-title":"The challenges of Bacillus of Calmette-Gu\u00e9rin (BCG) therapy for high risk non muscle invasive bladder cancer treatment in older patients","volume":"9","author":"Racioppi","year":"2018","journal-title":"J Geriatr Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2023.05.019_bib0028","first-page":"e140","article-title":"Association between socioeconomic status and the development of mental and physical health conditions in adulthood: A multi-cohort study","volume":"5","author":"Kivim\u00e4ki","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.urolonc.2023.05.019_bib0029","doi-asserted-by":"crossref","first-page":"231","DOI":"10.3389\/fpubh.2020.00231","article-title":"Socioeconomic status and access to healthcare: Interrelated drivers for healthy aging","volume":"8","author":"McMaughan","year":"2020","journal-title":"Front Public Health"},{"issue":"4","key":"10.1016\/j.urolonc.2023.05.019_bib0030","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s13187-016-1024-3","article-title":"The relationship between survivors\u2019 socioeconomic status and reports of follow-up care discussions with providers","volume":"32","author":"DiMartino","year":"2017","journal-title":"J Cancer Educ"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923001941?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923001941?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:27:38Z","timestamp":1761042458000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923001941"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1078143923001941"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.05.019","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Underutilization of intravesical chemotherapy and immunotherapy for high grade non-muscle invasive bladder cancer in California between 2006\u20132018: Effect of race, age and socioeconomic status on treatment disparities","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.05.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}